ClinicalTrials.gg
RecruitingNCT06897475Updated Nov 4, 2026

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

A Phase 2 interventional study of LY3457263 and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Recruiting at 60 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Nov 4, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company — 10 open to participants now, 21 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Eli Lilly and Company.

Planned enrollment
112th of 232
200 · median 181
Started
2025
with 14 others
Phase 2
34 of 238
2 open now
Primary completion
2027-05
later than 7 of 20 live
Registered
219th of 238
by date

Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 112th largest by planned enrollment of the 232 interventional ones that give a count, is one of 15 that started in 2025, is one of 34 in phase 2, reaches primary completion later than 7 of the 20 other live ones, and was the 219th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

10 of the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes
  • Have ≥7.5% to ≤10.5% at screening
  • Have a (BMI) of ≥27 kilograms per square meter (kg/m2) at screening
  • Have had a stable body weight for the three months prior to screening
  • On stable treatment dose of one of the following incretins for at least three months prior to screening:

    • Injectable semaglutide (1 and 2 milligram (mg))
    • Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg)

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes, latent diabetes, or history of ketoacidosis or hyperosmolar coma
  • Have a prior or planned surgical treatment for obesity
  • Have any of the following cardiovascular conditions within three months prior to screening:

    • acute myocardial infarction
    • cerebrovascular accident (stroke)
    • unstable angina, or
    • hospitalization due to congestive heart failure
  • Have used insulin to control blood glucose within the past year (short-term use allowed)
  • Current use of prohibited oral antihyperglycemic medication (OAM) (including but not limited to, Dipeptidyl Peptidase IV Inhibitors (DPP-4i) and meglitinides) may be randomized if the prohibited OAM treatment was discontinued at least 3 months prior to screening

    • If participant has been on stable doses (for at least three months) of up to three permitted OAMs (limited to metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, sulfonylurea, and/or thiazolidinediones (TZD), they are permitted to participate in the study
  • Have taken any medications or alternative remedies for weight loss within three months prior to screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    LY3457263 Dose 1

    Participants will receive LY3457263 subcutaneously (SC)

    Drug: LY3457263

  • Experimental
    LY3457263 Dose 2

    Participants will receive LY3457263 SC

    Drug: LY3457263

  • Experimental
    LY3457263 Dose 3

    Participants will receive LY3457263 SC

    Drug: LY3457263

  • Placebo comparator
    Placebo

    Participants will receive placebo SC

    Drug: Placebo

Interventions

  • Administered SC

  • DrugPlacebo

    Administered SC

This study also gives Semaglutide, Tirzepatide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change from Baseline in Fasting Serum Glucose

    Time frame: Baseline, Week 24

  2. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 24

07

Study locations

55 of 60 sites recruiting
  • Helios Clinical Research - Phoenix
    Phoenix, Arizona 85028, United States
    Recruiting
    • · Contact480-372-5996
    • David Francyk · Principal investigator
  • Wolverine Clinical Trials
    Santa Ana, California 92706, United States
    Recruiting
    • · Contact714-617-2426
    • Behnam Khaleghi · Principal investigator
  • Renstar Medical Research
    Ocala, Florida 34471, United States
    Recruiting
    • · Contact352-629-5800
    • David Oliver · Principal investigator
  • Oviedo Medical Research
    Oviedo, Florida 32765, United States
    Recruiting
    • · Contact407-977-2705
    • Bradley Block · Principal investigator
  • Balanced Life Health Care Solutions/SKYCRNG
    Lawrenceville, Georgia 30046, United States
    Recruiting
    • · Contact770-696-4541
    • Nadia Cameron, MD · Principal investigator
  • Physicians Research Associates
    Lawrenceville, Georgia 30046, United States
    Recruiting
    • · Contact678-252-2375
    • Ola Odugbesan · Principal investigator
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
    Recruiting
    • · Contact470-317-3604
    • Dwight Blake · Principal investigator
  • North Georgia Clinical Research
    Woodstock, Georgia 30189, United States
    Recruiting
    • · Contact678-494-5735
    • Bram Wieskopf · Principal investigator
  • Elite Clinical Trials
    Rexburg, Idaho 83440, United States
    Recruiting
    • · Contact208-356-8977
    • Brian Beesley · Principal investigator
  • Investigators Research Group
    Brownsburg, Indiana 46112, United States
    Recruiting
    • · Contact317-852-8280
    • Kenneth Maynard · Principal investigator
  • Clinical Research of Philadelphia
    Pennington, New Jersey 08534, United States
    Recruiting
    • · Contact215-676-6696
    • Taher Modarressi · Principal investigator
  • NYC Research INC
    Long Island City, New York 11106, United States
    Recruiting
    • · Contact516-574-9232
    • Anastasios Manessis · Principal investigator
  • Richmond University Medical Center
    Staten Island, New York 10310, United States
    Recruiting
    • Lina Leykina · Principal investigator
  • Southgate Medical Group
    West Seneca, New York 14224, United States
    Recruiting
    • · Contact716-712-1004
    • Brian Snyder · Principal investigator
  • Lucas Research, Inc.
    Morehead City, North Carolina 28557, United States
    Recruiting
    • · Contact252-222-5700
    • Kathryn Lucas · Principal investigator
  • Shelby Clinical Research
    Shelby, North Carolina 28150, United States
    Recruiting
    • · Contact980-552-9230
    • Christian Martin · Principal investigator
  • Providence Health Partners-Center for Clinical Research
    Dayton, Ohio 45439, United States
    Recruiting
    • · Contact937-297-8994
    • Paul Opsahl · Principal investigator
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma 73069, United States
    Recruiting
    • · Contact405-701-8999
    • Lisa Connery · Principal investigator
  • Frontier Clinical Research, LLC
    Scottdale, Pennsylvania 15683, United States
    Recruiting
    • · Contact724-220-5281
    • Tiffany Pluto · Principal investigator
  • Juno Research
    Houston, Texas 77040, United States
    Recruiting
    • · Contact713-779-5494
    • Damaris Vega · Principal investigator
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
    Recruiting
    • · Contact214-693-0904
    • Sumana Gangi · Principal investigator
  • Texas Diabetes & Endocrinology, P.A.
    Round Rock, Texas 78681, United States
    Recruiting
    • · Contact512-334-3505
    • Srujana Yada · Principal investigator
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
    Recruiting
    • · Contact210-545-4900
    • Michelle Welch · Principal investigator
  • Texas Valley Clinical Research
    Weslaco, Texas 78596, United States
    Recruiting
    • · Contact956-431-8090
    • Eduardo Luna · Principal investigator
  • Eastside Research Associates
    Redmond, Washington 98052, United States
    Recruiting
    • · Contact425-869-6828
    • Chad Crystal · Principal investigator
  • Centricity Research Brampton Endocrinology
    Brampton, L6S 0C6, Canada
    Recruiting
    • · Contact905 595 0560
    • Harpreet Bajaj · Principal investigator
  • Ecogene-21
    Chicoutimi, G7H 7K9, Canada
    Recruiting
    • · Contact418-545-1252
    • Daniel Gaudet · Principal investigator
  • Winterberry Research Inc.
    Hamilton, L8J 0B6, Canada
    Recruiting
    • · Contact365-366-6267
    • Steven Zizzo · Principal investigator
  • Viacar Recherche Clinique
    Longueuil, J4H 4B9, Canada
    Recruiting
    • Genevieve Mathieu · Principal investigator
  • G A Research Associates
    Moncton, E1G 1A7, Canada
    Recruiting
    • · Contact506-852-9865
    • Jocelyn Cormier · Principal investigator
  • Bluewater Clinical Research Group Inc.
    Sarnia, N7T 4X3, Canada
    Recruiting
    • · Contact1 (519) 344-6612
    • John O'Mahony · Principal investigator
  • Maple Leaf Research
    Toronto, M5G 1K2, Canada
    Recruiting
    • · Contact4164657936
    • Graham Smith · Principal investigator
  • Diabetes Heart Research Centre
    Toronto, M6G 1M2, Canada
    Recruiting
    • · Contact4169245871
    • Luis Noronha · Principal investigator
  • Fadia El Boreky Medicine
    Waterloo, N2J 1C4, Canada
    Recruiting
    • · Contact519-569-7592
    • Fadia El Boreky · Principal investigator
  • InnoDiab Forschung Gmbh
    Essen, 45136, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Velocity Clinical Research, Leipzig
    Leipzig, 04177, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Gemeinschaftspraxis Dr. Taeschner/Dr. Bonigut
    Leipzig, 04249, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Institut für Diabetesforschung GmbH Münster
    Münster, 48145, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • RED-Institut GmbH
    Oldenburg, 23758, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Legeartis - Poradnie Specjalistyczne
    Bialystok, 15-404, Poland
    Recruiting
    • · Contact48 507 18 11 18
    • Anna Modzelewska · Principal investigator
  • Centrum Badan Klinicznych PI-House sp. z o.o.
    Gdansk, 80-546, Poland
    Recruiting
    • · Contact48603790004
    • Monika Lukaszewicz · Principal investigator
  • Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET
    Krakow, 31-261, Poland
    Recruiting
    • · Contact48126237122
    • Joanna Mirocka · Principal investigator
  • Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna
    Lodz, 90-338, Poland
    Recruiting
    • · Contact607536360
    • Malgorzata Jozefowska · Principal investigator
  • Ekamed
    Lublin, 20-718, Poland
    Recruiting
    • · Contact48603787884
    • Ewa Skokowska · Principal investigator
  • Private Practice - Dr. Robert Witek
    Tarnów, 33-100, Poland
    Recruiting
    • · Contact48721000040
    • Robert Witek · Principal investigator
  • NBR Polska
    Warsaw, 00-710, Poland
    Recruiting
    • · Contact48514876203
    • Katarzyna Klodawska · Principal investigator
  • Szpital Czerniakowski
    Warsaw, 00-737, Poland
    Recruiting
    • · Contact4847722052
    • Olga Turowska · Principal investigator
  • 4 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ
    Wroclaw, 50-981, Poland
    Recruiting
    • · Contact71 7210 873
    • Mateusz Tabin · Principal investigator
  • Centro de Endocrinologia Alcantara Gonzalez
    Bayamón, 00956, Puerto Rico
    Recruiting
    • · Contact7877870933
    • Altagracia Alcantara-Gonzalez · Principal investigator
  • Mgcendo Llc
    San Juan, 00921, Puerto Rico
    Recruiting
    • · Contact7874842757
    • Martha Gomez-Cuellar · Principal investigator
  • FutureMeds - Birmingham
    Birmingham, B21 9RY, United Kingdom
    Recruiting
    • · Contact0121 592 2050
    • Tehmina Ahmed · Principal investigator
  • Layton Medical Centre
    Blackpool, FY3 7EN, United Kingdom
    Recruiting
    • · Contact441253951943
    • Rebecca Clark · Principal investigator
  • Southmead Hospital
    Bristol, BS10 5NB, United Kingdom
    Recruiting
    • · Contact0117 4148125
    • Georgina Russell · Principal investigator
  • FutureMeds - Liverpool
    Bromborough, CH62 6EE, United Kingdom
    Recruiting
    • · Contact01513150090
    • Connor McGladdery · Principal investigator
  • Futuremeds-Newcastle
    Newcastle, NE6 1SG, United Kingdom
    Recruiting
    • William Aspinall · Principal investigator
  • Newquay Health Centre
    Newquay, TR7 1RU, United Kingdom
    Recruiting
    • · Contact01637857903
    • Rutesh Patel · Principal investigator
  • George Eliot Hospital
    Nuneaton, CV10 7DJ, United Kingdom
    Recruiting
    • · Contact02476153592
    • Ponnusamy Saravanan · Principal investigator
  • The Adam Practice
    Poole, BH16 5PW, United Kingdom
    Recruiting
    • · Contact01202 339050
    • Patrick Moore · Principal investigator
  • Clifton Medical Centre
    Rotherham, S65 1DA, United Kingdom
    Recruiting
    • · Contact01709363950
    • Matthew Capehorn · Principal investigator
  • Rame Group Practice
    Torpoint, PL11 2TB, United Kingdom
    Recruiting
    • · Contact(0044) 1752 817900
    • Susan Keast · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for May 2027, 26 months after the start.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 26 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Mar 27, 2025
StartActual
Mar 28, 2025
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Velocity Clinical Research, Leipzig is now Active, not recruiting
Nov 4, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Futuremeds-Newcastle · Newcastle, United KingdomContact •••6109→none listedContact removed (no phone or email listed)
  • Velocity Clinical Research, Leipzig · Leipzig, GermanyContact removed •••5556Contact removed (no phone or email listed)
across 2 updates, Oct 9, 2026 – Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Velocity Clinical Research, Leipzig is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Velocity Clinical Research, Leipzig · Leipzig, GermanyContact removed •••5556Contact removed (no phone or email listed)
    + 1 other change: verification date
  2. Oct 9, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Futuremeds-Newcastle · Newcastle, United KingdomContact •••6109→none listedContact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06897475
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Mar 28, 2025
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nisotirostide

Start the discussion